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Abstract
Background: The current state-of-the-art in cancer diagnosis and treatment is not ideal; diagnostic tests are
accurate but invasive, and treatments are “one-size fits-all” instead of being personalized. Recently, miRNA’s have
garnered significant attention as cancer biomarkers, owing to their ease of access (circulating miRNA in the blood)
and stability. There have been many studies showing the effectiveness of miRNA data in diagnosing specific cancer
types, but few studies explore the role of miRNA in predicting treatment outcome.
Methods: Here we go a step further, using tissue miRNA and clinical data across 21 cancers from the ‘The Cancer
Genome Atlas’ (TCGA) database. We use machine learning techniques to create an accurate pan-cancer diagnosis
system, and a prediction model for treatment outcomes. Finally, using these models, we create a web-based tool
that diagnoses cancer and recommends the best treatment options.
Results: We achieved 97.2% accuracy for classification using a support vector machine classifier with radial basis. The
accuracies improved to 99.9–100% when climbing up the embryonic tree and classifying cancers at different stages.
We define the accuracy as the ratio of the total number of instances correctly classified to the total instances. The
classifier also performed well, achieving greater than 80% sensitivity for many cancer types on independent validation
datasets. Many miRNAs selected by our feature selection algorithm had strong previous associations to various cancers
and tumor progression.
Then, using miRNA, clinical and treatment data and encoding it in a machine-learning readable format, we built a
prognosis predictor model to predict the outcome of treatment with 85% accuracy. We used this model to create
a tool that recommends personalized treatment regimens.
Both the diagnosis and prognosis model, incorporating semi-supervised learning techniques to improve their
accuracies with repeated use, were uploaded online for easy access.
Conclusion: Our research is a step towards the final goal of diagnosing cancer and predicting treatment
recommendations using non-invasive blood tests.
Keywords: miRNA, Cancer diagnosis, Pan-cancer, TCGA dataset
Background
MicroRNAs (also known as miRNAs) are a family of
non-coding regulatory RNA genes that are involved in
RNA silencing and downregulation of gene expression.
They accomplish this by binding to mRNA, preventing
translation (translational silencing) and speeding up
deadenlyation (Poly-A tail breakdown). The first miRNA
was discovered in 1993 in the roundworm Caenorhabditis
elegans [1]. Since then, our knowledge of miRNA has
grown exponentially. MiRNA can function to prevent cell
division and drive terminal differentiation. An implication
of this is that downregulation of some miRNAs might play
a causal role in the generation or maintenance of tumors
[2, 3]. Calin et al. [4] first reported miRNA’s role in cancer,
after finding frequent deletions and dysregulation of two
miRNAs in lymphocytic leukemia. Since then, many
studies have established links between miRNA and onco-
genesis. MiRNA expression profiles have previously been
used to classify cancer and normal tissues and as
biomarkers for prognosis [5–8].
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In addition to suggesting the presence of cancer,
miRNA expression also contains valuable information
about the type, severity and prognosis of tumors [9].
This implies that miRNA profiles could potentially be
used to recommend tumor-specific treatments instead of
the “one-size-fits-all’ treatments that are often recom-
mended by doctors.
In multiple studies, miRNA profiles of tumor tissue
and adjacent normal tissue have been used to create pre-
dictive models for specific tumors. These studies focused
on a relatively small number of samples. Lu et al. [6],
after analyzing 217 mammalian miRNAs from 333
tumor samples consisting of tumors of lung, lymphoma
and bone, discovered that miRNA expression profiles of
tumors cluster based on developmental lineage. They
used hierarchical clustering analysis to show that cancers
of epithelial origin are clearly differentiated from cancers
of the gastrointestinal tract. They further used clustering
analysis among the samples of acute lymphocytic
leukemia (ALL) to discover that different ALL subtypes
tend to cluster together. Rosenfeld, Nitzan et al. [10]
studied miRNAs from tumor and metastatic cancer to
prove that they could predict the cancer tissue of origin
(22 tumor types into 7 different tissue types) using KNN
and decision tree classifiers. They achieved 89% classifi-
cation accuracy during validation. Both these studies are
limited by the number of samples (less than 400
samples) and the focus on classifying tissue of origin,
where multiple tumors originating from the same tissue
are classified as one class. Identifying the actual cancer
type (as opposed to the tissue of origin) with as few
miRNA as possible helps make it possible to diagnose
specific cancer types from miRNA expression levels of
circulating tumor cell miRNA in the blood [11, 12].
Although extensive research has been done on expres-
sion levels of specific miRNA to predict the prognosis of
diseases like cancer, very few researchers explored the
next natural topic: the role of miRNA expression profiles
from the tumor tissue in predicting how successful a
cancer treatment will be. Villaruz et al. [13] studied the
effectiveness of miRNA as biomarkers in predicting the
outcome of melanoma for patients who took a specific
treatment. However, there is not enough previous pan--
cancer analysis of predicting treatment effectiveness
using miRNA data. With the advent of the TCGA pan-
cancer analysis project, vast amounts of molecular and
clinical data from tumorous and normal tissues,
spanning over 34 different types of cancers, are at the
fingertips of researchers [14].
In this study, we used the vast amount of tissue
miRNA data available for different cancer types in the
TCGA pan-cancer project to build a parsimonious
multivariate model that can accurately classify cancer
type. Our results show that the support vector machine
based model could classify individual cancer types with
an overall accuracy of 97.2% with most of the per-cancer
sensitivities well above 95%, as well as classifying with
above 80% sensitivity for most cancers on an independ-
ent validation set. Next, we investigated whether progno-
sis could be predicted given clinical information, the
course of treatment taken and miRNA expression levels
at the time of diagnosis. By combining miRNA expres-
sion data with clinical information in a machine
learning-parseable format, we were able to predict the
prognosis with 85% accuracy. Because this result was 8%
more accurate than the accuracy without miRNA data,
we showed that miRNA data does make a significant
impact on prognosis. Finally, we built a web-based tool
where a user can upload miRNA expression and clinical
data and receive an automated diagnosis. We added
semi-supervised learning to our web-based tool, and the
tool automatically re-trains the classifiers with new
uploaded data.
Methods
Data preprocessing and modeling
We used the R language (version 3.2.3) and CRAN pack-
age ‘caret’ version 6.0 for preprocessing and building
classifier models [15]. The WEKA 3.6.13 feature suite
was used for feature selection algorithms [16]. For both
cancer classification and treatment recommendation, we
used the normalized miRNA expression profiles from
TCGA pan-cancer analysis project [17]. TCGA database
has miRNA samples for 34 different tumor types
obtained from GPL11154 (Illumina Hiseq 2000) plat-
form. However, some tumor types were discarded due to
low sample sizes (less than five samples per tumor type).
After this selection, 5229 samples from 21 different
tumor and normal tissues remained (see Table 1). These
21 cancer types span across various organs and systems.
A few of these cancer types (Lung Squamous Cell
Carcinoma, Stomach Adenocarcinoma, Liver Hepatocel-
lular Carcinoma, Thyroid Carcinoma, Kidney Chromo-
phobe and Kidney Renal Papillary Cell carcinoma) have
significant number of normal tissue samples as well in
the dataset. But, many cancer types either have very few
corresponding normal samples or no normal samples.
Also, the samples have missing miRNA values. These
missing miRNA value estimation was done using a
k-Nearest-Neighbor imputation algorithm [18]. A
threshold value of 0.2 was used to eliminate miRNA
features that were not present in more than 20% of sam-
ples. Finally, the miRNA data was log transformed and
standardized to zero mean and unit variance.
Building a cancer classifier
We built several multi-class classifiers (SVM linear, SVM
radial, Random Forest, Linear Discriminant Analysis and
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Naïve Bayes) and validated them using 10-fold cross valid-
ation, repeated ten times. These classifiers are trained to
classify 21 different cancer types and the normal tissue
type from the miRNA expression values. During the
training (for each fold), we used two-stage feature selec-
tion algorithm. In the first stage, we used a correlation
based feature selection algorithm [19] to remove features
that showed no meaningful Pearson correlation with the
output. During the second stage, recursive feature elimin-
ation algorithm (from the caret package in R) was used to
narrow down the feature set to 60 features while picking a
strong feature set that would not compromise the classifi-
cation performance.
The classifier with highest overall accuracy, aggregated
across all validation tests, was selected and analyzed for
misclassifications. Overall accuracy (or the classifier
accuracy) is defined the ratio of all correctly classified
instances over the total instances during the testing
phase of each iteration in the 10-fold cross validation.
Similarly, per-class accuracy is defined as the ratio of the
correctly classified instances of a particular class to the
total number of instances of that class. Next, we used
the kappa statistic – as a measure of the agreement as com-
pared to the likely agreement due to chance alone – to
evaluate the classifiers. We also measured per class training
sensitivities and specificities of the classifier that had the
highest overall accuracy and kappa statistic.
Since the feature selection is done during training
phase of each of the ten iterations in 10-fold cross valid-
ation, features selected could differ between iterations.
We took the common features from all the iterations
and analyzed the features using the IPA core analysis
tool (IPA ® QIAGEN, Redwood City, www.qiagen.com/
ingenuity) to find the diseases/functions and networks
enriched by this subset. This analysis gives insight into
whether our classifier performance is driven by tissue
specific miRNAs or cancer/tumor specific miRNAs.
Tissue/Organ/Origin prediction
Studies have shown that miRNA from tissues with similar
anatomical locations correlate well [20]. Thus, we further
investigated whether miRNA expression values from
cancerous tissues also correlate along anatomical locations
and if the correlation follows tissue development hierarch-
ies. To formalize this, each cancer site was assigned to leaf
nodes in the embryonic development tree [21] (Fig. 2).
Then, by walking up the tree, classification was compared
at three stages of the developmental tree. For example,
Table 1 Distribution of the cancer and normal samples in the dataset used to build the predictive model (TCGA cancer classifier)
Organ/System Cancer Cancer acronym Normal samples Cancer samples
Thymus Thymoma THYM 2 124
Lung Lung Squamous Cell Carcinoma LUSC 45 342
Pancreas Pancreatic Adenocarcinoma PAAD 4 179
GI tract Cholangiocarcinoma CHOL 9 36
Esophageal Carcinoma ESCA 13 185
Stomach Adenocarcinoma STAD 41 395
Liver Liver Hepatocellular Carcinoma LIHC 50 374
Thyroid Thyroid Carcinoma THCA 59 510
Adipose Adrenocortical carcinoma ACC 0 80
Lymph Diffuse Large B-cell Lymphoma DLBC 0 47
Heart Mesothelioma MESO 0 87
Reproductive Cervical Squamous Cell and Endocervical
Adenocarcinoma
CESC 3 309
Ovarian Serous Cystadenocarcinoma OV 0 461
Testicular Germ Cell Tumors TGCT 0 156
Urinary Uterine Carcinosarcoma UCS 0 56
Kidney Kidney Chromophobe KICH 25 66
Kidney Renal Papillary cell carcinoma KIRP 34 292
Brain Brain Lower Grade Glioma LGG 0 526
Peripheral Nervous System Pheochromocytoma and Paraganglioma PCPG 3 184
Epidermis Skin Cutaneous Melanoma SKCM 2 450
Uveal Melanoma UVM 0 80
Note that not all the cancer types have normal samples. Even though the TCGA dataset has about 33 cancer types, many cancer types were removed due to lack
of data (less than 5 samples) and in the end 21 cancer types as listed in this table were used for the classification
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stomach adenocarcinoma was classified as a cancer of GI
tract at stage 3, a cancer of gut tube origin at stage 2 and a
cancer of endoderm origin at stage 1.
Independent validation
Next, for independent validation of our SVM based classi-
fiers, we obtained three miRNA datasets from GEO data-
base [22] and validated the performance using those
datasets. Due to the lack of open access datasets for the
majority of cancer types in our 21-cancer SVM classifier,
we had to use cancer types that our model was not trained
on. We used our Stage III classifier, which classifies these
cancers by tissue/organ type, with these datasets. The
GSE2564 series uploaded by Jun et al. [6] contains miRNA
expression values for 200+ cases spanning across 12 differ-
ent cancer types. The GSE68839 series uploaded by
Vergani et al. [23] contains miRNA data for eight
melanoma samples. The GSE21847 series uploaded by
Montes-Moreno et al. [24] had 29 samples of B-cell
Lymphoma. We used log2 normalized expression values
from these data sets and further standardized the datasets
individually to have zero mean and unit variance.
Prognosis prediction
The TCGA database contains clinical data for some, but
not all, patients. This data includes clinical data such as
ethnicity, gender, the type of treatments and drugs used,
and a description of the outcome (e.g. whether the can-
cer recurred or not). Out of the 5229 patients, complete
clinical information is available for about 710 patients.
When selecting the samples for building the treatment rec-
ommendation tool, only the samples with the below criteria
were retained: (1) contains clinical information: gender, age
and ethnicity, the type of treatment received and if the
tumor went under remission after 300 days or more. (2)
There are at least five samples for each cancer type (3)
There are at least five samples for each unique treatment.
This data set is further divided into training and testing
with 75–25 split. All the unique treatments from the train-
ing samples were extracted. In order to represent the treat-
ment in a form that machine learning models could easily
interpret, treatment data items were first converted into a
canonical bag-of-strings form of “general treatment, spe-
cific method;” and then sorted in alphabetical order and
combined (Additional file 1). First, we used the Levensh-
tein/edit distance to define a similarity metric between pa-
tients with different treatments. Next, we mapped these
distances into 3-dimensional space. A 3-dimensional point
Pk was attached to each treatment k, and an attempt was
made to minimize the difference between 3D distances and
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. R provides
a solution to problems of this form (often called Cox
scaling problems) with the package “cmdscale”. This ana-
lysis was done on the unique treatment list to obtain three
numeric coordinates for each treatment. Then, a support
vector machine model was trained on a combination data
set featuring miRNA data, clinical data, cancer type, and
treatment type (in 3D coordinate form) to predict the clin-
ical outcome (i.e. recurrence or remission status after at
least 300 days). The SMOTE algorithm [25] was used to
correct class imbalance caused by low number of samples
where disease reoccurred compared to remission samples.
The model with highest accuracy and per-class sensitivities
on the test data set was chosen as the prognosis predictor
tool. The prognosis predictor model output is a score (be-
tween 0 and 1) that indicates the probability of remission.
Web tool development
Next, we developed a treatment recommendation algo-
rithm based on our prognosis model. The algorithm
works as follows:
Given miRNA information and clinical data for a pa-
tient, this algorithm cycles through all possible treatments
from the unique treatment lists obtained in the previous
analysis, and for each treatment, predicts the probability
of remission using the prognosis predictor tool. Then, the
treatment that results in the highest probability of remis-
sion is picked as the recommended treatment.
Then, using the RStudio shiny package (version 0.12)
[26], a web application was built. In this web application,
our SVM classifier and the treatment recommendation
tools were hosted on a server and the web application
runs in a browser. Using the user interface for this appli-
cation, user can upload clinical information using dialog
boxes, with miRNA information in a CSV file.
The data will be sent to the servers where the application
pre-processes the data, including imputing missing miRNA
values (removing miRNAs with more than 20% missing),
then uses the saved classification and treatment recommen-
dation models to diagnose cancer type and makes three
different treatment recommendations. A semi-supervised
learning algorithm with the potential to improve the accur-
acy of both models was implemented. In this algorithm, the
newly uploaded training samples classified with a probabil-
ity over a threshold p = 0.95 are periodically added to the
database, and the models have the opportunity to retrain
and adjust based on these samples.
Results and discussion
Cancer diagnosis and classification
Out of the 2588 miRNA features, 2118 miRNA were
removed during pre-processing as more than 20% of the
samples had missing values for these miRNA leaving a
feature set of 470 miRNAs. Most of the missing miRNA
values were systemically missing across all cancer types.
Using this feature set, different classifiers (Naïve Bayes,
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Logistic Model Tree, KNN and Linear SVM) were built
and the overall accuracy and kappa statistics were
compared (Fig. 1).
The radial SVM classifier was chosen as it reported
the highest accuracy, 97.2%. This classifier also has the
highest Kappa statistic of 0.97. Per-cancer sensitivities
and specificities of this classifier were listed in Table 2.
Table 3 contains the confusion matrix of this classifier.
Most of the sensitivities are above 90%, except for
ESCA, esophageal adenocarcinoma and CHOL, cholan-
giocarcinoma. Further inspection of the confusion
matrix in Table 3 revealed that, 11% of CHOL cases
were classified as pancreatic adenocarcinoma (PAAD).
12% of the ESCA cases were classified as Stomach
Adenocarcinoma (STAD) and 6% of the ESCA cases
were classified as liver hepatocellular carcinoma (LIHC).
The STAD, CHOL and ESCA cancers are from the gastro-
intestinal (GI) tract and share a common developmental
origin (Fig. 2). Similarly, PAAD or cancers in the pancreas
and LIHC are related to the other three cancers due to a
similar developmental parent (i.e. gut tube).
Predictably, the results improve dramatically when
walking up the embryonic origin tree diagram and classi-
fying at different stages. Table 4 lists the overall sensitiv-
ities when classifying at different stages of the
embryonic development tree. Sensitivities slowly in-
crease at the higher levels with accuracies reaching to
100% at the germ layer (Stage 1). For example, the ESCA
(esophageal cancer) class is detected with 82% sensitivity
initially, but when it is combined with other gastrointes-
tinal cancers to form the subtype GI tract, the sensitivity
jumps to 0.98 with Stage III classifier. Then, when
classified as a gut tube cancer, the sensitivity increases
even further with the Stage II classifier. These increases
are more than would be expected by chance aggregation
alone and hint at a relation between cancer differenti-
ation and the embryonic origin tree diagram.
The first level of feature selection yielded 132 predict-
ive miRNA features. The second level yielded 60 miRNA
features. Table 2 also lists the per-class performance of
the classifier for 132 and 60 features. The classifier built
with 60 features achieved an overall accuracy of 95.5%
with per-class sensitivities above 95% for many cancer
types. Note that, due to the scarcity of the normal
samples, all the normal tissue samples were put together
under a single class in these classifiers. The per-class
sensitivities and specificities of the ‘Normal” class were
95 and 99% respectively, indicating the ability of the
classifier to distinguish between the many cancer types
from the normal tissues.
These results suggest that miRNA can be used to pre-
dict diagnosis with extremely high accuracy, sensitivity,
and specificity.
The results from IPA core analysis on the 60 miRNA fea-
tures used by our classifier are summarized in Additional
file 2. As seen from this table, 49 out of the 60 molecules
are highly correlated with cancer. The top two disease
categories enriched by our miRNA features are metastatic
solid tumor (p-value of 3.27E-53) and advanced malignant
solid tumor (p-value of 1.61E-50). Similarly, the top three
networks enriched by these set of miRNA are related to
cancer, organismal injury and abnormalities and gastro-
intestinal diseases (Additional file 3: Table S1). IPA com-
putes the p-value for a function/process as the measure of
Fig. 1 Performance metrics for multiclass classifiers. Accuracy and kappa statistics for the 7 multiclass classifiers that we evaluated, using boxplots
to reflect classifier variability over multiple runs
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likelihood that the association between that function
and set of molecules (in our case, miRNAs) is due to a
random chance. The smaller the p-value (or the higher
the negative log of the p-value), the higher the likeli-
hood that there is a significant association. P-value was
obtained using Benjamini-Hochberg method to account
for multiple testing [27].
The high negative log p-values for association between
the cancer/tumor progression and the miRNA features
used by our classifier suggest that the classifier was able
to select and classify these 21 different cancer types
using key miRNA features previously known to be asso-
ciated with many cancer types. The features were
predominantly cancer specific (rather than tissue
specific), hinting that tumor progression mechanisms
differ at the miRNA level between tissues.
We then analyzed the top three miRNAs (ranked by
our feature selection algorithm) from our 60 miRNA
features. The first one, let-7 family of miRNAs (hsa-let-
7i-5p, hsa-let-7d-3p) has been mentioned extensively in
the literature as the miRNA precursor that regulates cell
cycle progression and cancer [28–30]. Decreased expres-
sion of let-7 was known to cause unregulated cell
division and tumor formation [31]. The second feature,
mir-1-3p (mir-1 family) was studied by Hu et al. [32]; it
has been suggested that this miRNA plays a critical role
as a tumor activator for human liver hepatocellular car-
cinoma. Decreased expression of mir-1 could decrease
proliferation and induce apoptosis. Mir-10 family
(mir-10a and mir-10b) were studied extensively before
for their casual role in several cancer types. Lund et al.,
summarized the previous studies and reported that mir-
10 was dis-regulated in several cancer types including
Hepatocellular carcinomas, Pancreatic cancer, B-cell
Chronic Lymphocytic Leukemia and Melanoma [33].
These are all cancer types our classifier can distinguish.
This IPA analysis combined with our literature search
indicate that our SVM classifier was able to achieve
better performance using miRNAs previously known to
cause and promote tumor proliferation.
Table 2 SVM classifier performance
Per-cancer performance metrics for the SVM classifier with all features and with various feature subsets selected by two-stage feature selection algorithms. The
cells shaded in pink are the cancer types with sensitivities below 90%
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Table 3 Confusion matrix for the SVM classifier
This matrix is obtained by aggregating the results of 10-fold cross validation repeated 10 times. The rows represent the predictions and the columns represent
the true values. The entry values contain the fraction of the overall samples of a cancer type (represented by the column) that are predicted as the cancer type
represented by the row. Cells shaded in orange-red colors represent misclassifications greater than 5% of the total samples for that cancer type. For example, for
the ESCA cancer type, 11% of the ESCA cancer type samples were misclassified as STAD
Fig. 2 Mammalian developmental tree. Each of the 21 cancer types was assigned to its appropriate leaf node of the tree
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Independent validation
The GSE2564 and GSE21847 datasets have 50 and 39
miRNA features in common with the 60 miRNA features
used by our classifiers. The remaining miRNAs were im-
puted using the k-Nearest-Neighbor imputation algorithm
[18]. GSE68839 samples had miRNA values for all the 60
miRNA features. These three datasets were normalized
independently to have zero mean and unit variance.
Many cancer types in these three dataset don’t exactly
match the cancers our 21-cancer type SVM classifier
was trained to classify (Additional file 3: Table S2). Only
Pancreatic Adenocarcinoma (PAAD) and Diffuse Large
B-cell Lymphoma (DLBC) types matched one of the
cancer types our SVM classifier was trained to predict –
the rest were not cancer types from our dataset. To
circumvent this problem, we relied on the SVM classifier
at stage III (of the embryonic development tree, Table 4),
to classify based on the organs and tissue of origin and
predicted the cancer tissue/organ for the various cancer
types in the validation set. Confusion matrix from this
classification and the per class sensitivities and specific-
ities were given in the Additional file 3 Tables S3 and
S4). The cancers of epidermis, kidney, lymph nodes,
pancreas reproduction systems achieved sensitivities
greater than 70% (all cancers achieved high specificities).
Cancers of urinary tract performed poorly with a sensi-
tivity of 0.43 (four out of seven samples were incorrectly
classified). The drop in per class accuracy, compared to
our trained stage III SVM classifier could be attributed
to the differences in the platforms, missing miRNA fea-
tures (15% features missing in GSE2564 series and 33%
missing in GSE21847 series), lower overall sample size
and the fact that many of these cancers were from can-
cer types not in the TCGA dataset. But, the results are
still extremely promising, especially considering that
they were mainly on completely unseen cancer types.
They suggest that our Stage III classifier was able to
perform very well on an independent, unseen dataset in
the presence of platform variation.
Prognosis prediction
After merging treatments with edit distance less than 25
to reduce the number of unique treatments, a cohort of
476 patients with 9 unique cancer types and 29 unique
treatment types remained (Table 5) [see Fig. 3 for a
Table 4 SVM classifier performance at different stages of the embryonic development tree
Stage I classifier Stage II classifier Stage III classifier
Subtype Sensitivity Specificity Subtype Sensitivity Specificity Subtype Sensitivity Specificity
Endoderm 0.99 1 GI Tube 0.99 0.99 Thymus 0.98 1
Lung 0.98 1
Pancreas 0.96 1
GI Tract 0.98 1
Liver 0.98 1
Thyroid 1 1
Mesoderm 0.99 1 Lateral Plate Mesoderm 0.97 1 Adipose 0.98 1
Lymph 0.96 1
Heart 0.98 1
Intermediate Mesoderm 0.99 1 Reproductive 0.99 1
Urinary 0.98 1
Kidney 0.99 1
Ectoderm 1 1 Neural Ectoderm/Neural Tube 1 1 Brain 1 1
Neural Crest 0.99 1 Peripheral Nervous System 0.99 1
Surface Ectoderm 1 1 Epidermis 1 1
Climbing up the embryonic development tree, SVM classifiers were built at each stage to classify the cancers at different granularities. Stage 4 identifies the actual
cancer. Stage III classifier can classify the cancers at the tissue/organ level. At Stage I, the cancer is classified as belonging to one of the germ layers
Table 5 Distribution of the samples used in prognosis prediction
and treatment recommendation models




CESC 52 4 9
ESCA 23 4 5
LGG 137 6 88
LUSC 15 7 3
OV 111 9 23
PAAD 45 4 32
STAD 37 5 13
TGCT 51 4 6
UCS 13 2 3
Preprocessing the cohort of 710 patients with full clinical and treatment information
yielded a smaller subset of 476 patients
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graphical representation of the Cox scaling results.
Additional file 1 contains a subset of the unique treat-
ments.]. Using the clinical and miRNA data, a radial
SVM classifier was trained and validated with repeated
10-fold cross validation. Table 6 lists the classifier
results (aggregated over repeated cross validations)
with and without the miRNA data. The prognosis
predictor achieves 85% accuracy overall, showing
approximately 8% increase in the accuracy after add-
ing miRNA features to the classifier. These results
suggest that miRNA play a significant role in the
prognosis of cancers.
Web tool development
The web tool was built according to specification and is
located at http://www.mirnanalyze.com. The tool was
tested extensively (on the web) using examples from
TCGA to ensure its results matched the results obtained
by standalone R scripts. As more researchers and labs
begin to use the web tool developed, it will collect more
unlabeled data and we will ideally be able to evaluate the
effects of our semi-supervised learning algorithm.
In summary, for cancer diagnosis, we saw hints that
cancers were differentiated somewhat based on embry-
onic tissue-of-origin. For future research, it would be
interesting to explore exactly how similar cancers with
the same embryonic tissue of origin are, as well as
what causal factors underlie the relation between these
two phenomena.
For treatment prediction, an issue affecting our accur-
acy negatively was the existence of “invisible” causal
factors, other conditions not collected by the TCGA.
The accuracies were also affected by the very few sam-
ples with full clinical and treatment data. Due to these
limitations, the tool, in its current state, is not ready to
be used in clinical settings. The tool would need to be
trained with more features and more samples with and
without remission for each treatment and cancer type.
Recently, cell free miRNAs have garnered lot of atten-
tion as potential blood based biomarker for cancer. We
could potentially test our classifier performance in
detecting cancers from the cell-free miRNA expression
values from blood serum/plasma; this would be of
immense clinical significance.
Medical automation is one of the most fruitful fields
in research today. All of the work presented here and all
of the future research planned are dedicated towards
one specific goal; that in the near future, physicians will
be able to take a blood sample from any patient
suspected of having cancer, immediately analyze it on-
line, and receive a diagnosis with multiple treatment
options. The authors hope that this research is one step
on the journey to that final goal.
Conclusions
We successfully built a miRNA based classifier that
can classify between 21 different cancer types with
97.2% overall classification accuracy (with per class
accuracies well above 905). This performance is 7%
better than the state-of-the-art. Our prognosis pre-
diction model was able to achieve 85% accuracy in
predicting the reoccurrence for a patient. We were
able to use this prognosis prediction classifier to
build a novel treatment recommendation system that
is uploaded at www.mirnanalyze.com.
The SVM classifier for cancer diagnosis achieved an
accuracy of 97.2% in repeated 10-fold cross validation
tests. It is the first ever model to integrate a large
cohort of patients (5229 patients) to classify 21 differ-
ent types of cancers. This high accuracy was obtained
Fig. 3 Cox scaling map. A graphical representation of the Cox scaling
map of treatment space. Uses the MATLAB “jet” colormap, with black
and red colors representing more prevalent treatments and green and
blue colors representing less prevalent treatments. The (x, y, z) axes simply
represent the 3 Cox-scaled coordinates assigned to each treatment.
Treatments with edit distances less than 25 were further merged to
form 29 unique treatments





Disease sensitivity 0.86 0.76
Disease specificity 0.84 0.77
Accuracy 0.85 0.77
Kappa statistic 0.71 0.53




Tuning parameters (Sigma) 0.01 0.16
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due to the large dataset, careful pre-processing and
imputation of the data, picking the best model and
tuning classifier parameters. Many of the misclassifi-
cations made by this classifier were between cancers
with similar embryonic origins, and the accuracies
improved to 99.9–100% when tree-climbing up the
embryonic developmental model, suggesting that
cancers originating from similar stem cells have simi-
lar molecular characteristics. The two-step feature
reduction yielded 60 miRNAs and a classifier using
these 60 miRNA was able to achieve 95.5% overall
accuracy.
A detailed functional analysis of these 60 miRNA features
using the IPA tool revealed that 49 of them are highly asso-
ciated with cancer and tumor metastasis (p-value < 0.05),
suggesting that the classifier was able to pick tumor specific
miRNA (as opposed to tissue specific miRNA) for these 21-
cancer type classifications.
We had promising results on an independent valid-
ation dataset. Despite our dataset being composed
mainly of cancer types that our SVM model was not
trained on, our classifier achieved high specificities on
all cancer types and around 70-80% sensitivity on all
but 3. Our model’s ability to classify completely un-
seen cancer types from an unseen dataset indicates its
generalizability.
Using clinical info, miRNA and treatment data, a prog-
nosis predictor tool was then built that achieved 85%
accuracy—an 8% improvement over a classifier that
predicts prognosis only based only on clinical and treat-
ment data. Table 6 compares AUC for the prognosis pre-
diction with and without the miRNA data. AUC is
significantly higher (0. 87) for prognosis prediction with
miRNA data. Because many hard-to-measure factors
such as diet, exercise, clinical history, and other clinical
information that was not collected affect prognosis, such
accuracy is high for a prognosis model.
Our web tool was deployed at www.mirnanalyze.com
and is available for predicting cancer type as well as
recommending 3 personalized treatment regimens to
improve remission probability.
This research distinguishes itself through:
 First integrated 21-cancer classifier that can detect
the type and presence of cancer with 97.2% overall
accuracy (over 7% more accurate than all previous
research).
 First attempt to model prognosis prediction
given the miRNA, clinical and treatment
information, and build a personalized treatment
regimen recommendation tool based on miRNA
profile data.
 First attempt to crowd-source diagnosis and
treatment tools to the public.
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